On the other hand, LM are becoming more common in patients with HER2+ subtypes of breast cancer, possibly as a result of advances in systemic anti‐HER2 therapy over the last decade, which have resulted in prolonged metastatic survival and better systemic disease control.14 This evidence concerns the gene ERBB2 and breast cancer.